Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Enoxaparin

First Posted Date: 2018-06-26

Last Posted Date: 2022-11-15

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 100

Registration Number: NCT03568838

Locations: 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Other: Thromboprophylaxis
Drug: Enoxaparin
Drug: Enoxaparin + Rosuvastatin

First Posted Date: 2018-05-22

Last Posted Date: 2025-01-23

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 24

Registration Number: NCT03532139

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women

Phase 4

Completed

Conditions: Enoxaparin
Placental Insufficiency

Interventions: Drug: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe
Drug: Aspirin 100 mg Oral Tablet, Enteric Coated

First Posted Date: 2018-05-18

Last Posted Date: 2020-07-02

Lead Sponsor: Les Laboratoires des Médicaments Stériles

Target Recruit Count: 89

Registration Number: NCT03528967

Locations: 🇹🇳
Maternity Center of Wassila Bourguiba Hospital - Department A, Tunis, Tunisia

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Conditions: Deep Vein Thrombosis
Surgery--Complications
Thrombosis

Interventions: Drug: Xarelto (rivaroxaban)
Drug: Lovenox (enoxaparin)

First Posted Date: 2018-03-30

Last Posted Date: 2018-03-30

Lead Sponsor: Hanoi Medical University

Target Recruit Count: 4000

Registration Number: NCT03483181

Locations: 🇻🇳
Hanoi Medical University, Hanoi, Vietnam

Prevention of Thromboembolic Events in Total Knee Replacement Patients

Phase 2

Withdrawn

Conditions: Thrombotic Disorders

Interventions: Drug: MAA868
Drug: Enoxaparin

First Posted Date: 2018-01-08

Last Posted Date: 2020-10-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03393481

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enoxaparin
Drug: Clexane

First Posted Date: 2017-12-06

Last Posted Date: 2017-12-06

Lead Sponsor: Rovi Pharmaceuticals Laboratories

Target Recruit Count: 46

Registration Number: NCT03363477

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Myocardial Ischemia
Unstable Angina
Myocardial Infarction

Interventions: Drug: Rivaroxaban 5 mg
Drug: Rivaroxaban 2.5 mg
Drug: Enoxaparin

First Posted Date: 2017-12-05

Last Posted Date: 2022-02-22

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 2055

Registration Number: NCT03363035

Locations: 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
The First Hospital of Changsha, Changsha, Hunan, China
🇨🇳
The Second People's Hospital of Hunan Province, Changsha, Hunan, China

and more 21 locations